Please login to the form below

Not currently logged in
Email:
Password:

Mereo BioPharma’s Richard Bungay to step down

Will leave CFO and COO roles in April 2017

Mereo BioPharma's Richard Bungay is set to step down from his roles as chief financial officer and chief operating officer in April 2017.

Bungay joined the UK-based clinical stage biopharmaceutical firm in July last year, taking on responsibility for Mereo BioPharma's finances, manufacturing and quality operations.

He has previously held the chief financial title at Glide Pharmaceutical Technologies, Chroma Therapeutics and Verona Pharma, remaining as a non-executive board director at both Glide and Chroma.

Prior to these roles, Bungay worked at Celltech Group as director of corporate communications and planning, and served as finance director for AstraZeneca's respiratory and inflammation therapy area.

Dr Peter Fellner, chairman of Mereo BioPharma, said: “On behalf of the board I would like to thank Richard for his significant contributions to the successful launch of the company and the subsequent introduction of its shares on AIM.

“We wish him every success for the future.”

10th October 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics